Human(ized) monoclonal antibodies in atopic patients - state of the art

Arzu Didem Yalcin; Kevser Onbasi; Rusen Uzun; Felix Herth; Philipp Albert Schnabel

doi:10.5114/ceji.2020.97909

Human(ized) monoclonal antibodies in atopic patients - state of the art

Cent Eur J Immunol. 2020;45(2):195-201. doi: 10.5114/ceji.2020.97909. Epub 2020 Jul 27.

Authors

Arzu Didem Yalcin^{1

2}, Kevser Onbasi³, Rusen Uzun⁴, Felix Herth⁵, Philipp Albert Schnabel⁶

Affiliations

¹ Department of Internal Medicine, Allergy and Clinical Immunology, Genomics Research Center, Academia Sinica, Taipei, Taiwan.
² Department of Allergy and Clinical Immunology, Antalya Training and Research Hospital, University of Medical Science, Antalya, Turkey.
³ Department of Internal Medicine, Allergy and Clinical Immunology, Dumlupinar University, Kütahya, Turkey.
⁴ Department of Pulmonology, Antalya Training and Research Hospital, University of Medical Science, Antalya, Turkey.
⁵ Department of Pulmonary and Critical Care Medicine, Thoraxklinik Translational Lung Research Center, University of Heidelberg, Heidelberg, Germany.
⁶ Department of Pathology, University of Heidelberg, Heidelberg, Germany.

Abstract

Asthma is an important chronic disease affecting a lot of people worldwide. Treatment options for asthma like biological agents are being developed more frequently nowadays. Despite a lot of treatment options, some patients still remain symptomatic. As more and more practitioners choose treatment with biologic agents as a convenient way of therapy, biologic agents and other valuable methods must be discovered in order to cope with a growing number of treatment agents. This manuscript emphasizes on new generation monoclonal human(ized) antibodies in asthmatics and off-label use . The first developed biologic agent is the anti-immunoglobulin E monoclonal antibody called omalizumab. Currently it is an approved treatment option for asthma.

Keywords: anti IL-5; asthma; humanized monoclonal antibodies; omalizumab.

Publication types

Review